Alfasigma to acquire the entire share capital of Sofar
Reading time 1 min Christian Fernsby ▼ | August 2, 2022Alfasigma S.p.A. has signed an agreement to acquire the entire share capital of Sofar S.p.A., an Italian pharmaceutical company with over half a century of operational history in the research, production and marketing of drugs, medical devices and food supplements.
Italy Alfasigma
Topics: Alfasigma Sofar
Sofar closed 2021 with a turnover of over 113 million euros, double-digit growth compared to the previous year. The company owns an advanced research laboratory located in Bergamo and a production plant in Trezzano Rosa (Milan).
Alfasigma is one of the leading pharmaceutical companies with Italian capital with a consolidated turnover of over one billion euros in 2021, research centers in Bologna and Pomezia, three production plants in Italy and two abroad, and about 3000 employees.
Both companies are focused on the gastrointestinal area.
Sofar carries out approximately 80% of its activity in this therapeutic area and has concentrated research on the microbiota within the Kilometro Rosso Science and Technology Park in Bergamo.
Alfasigma is developing a product pipeline focused on the gastrointestinal area where it can make the most of its important scientific know-how.
The integration of the two companies will lead to the expansion of the Alfasigma product range in Italy and on foreign markets.
The acquisition is expected to be completed in October 2022. ■
"It's essential to distinguish between events that are really beyond your control and events you caused yourself."
